Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 mutated AML

Russell, Nigel H., Othman, Jad, Cumming, Oliver Sebastian, Thomas, Abin ORCID: https://orcid.org/0000-0002-8283-6762, Tedjaseputra, Aditya, Potter, Nicola, Jovanovic, Jelena, Gilkes, Amanda Frances, Batten, Leona, Canham, Joanna ORCID: https://orcid.org/0000-0003-3482-0990, Hinson, Emily L., Runglall, Manohursingh, Aucken, Phoebe, Kottaridis, Panagiotis, Cavenagh, James Durrell, Arnold, Claire, Freeman, Sylvie D., Dennis, Mike, Knapper, Steven and Dillon, Richard James 2025. Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 mutated AML. Blood Advances , bloodadvances.2025017244. 10.1182/bloodadvances.2025017244

PDF - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB)

Abstract

Despite the use of FLT3 inhibitors, outcomes for patients with FLT3 mutated (FLT3mut) AML remain suboptimal because of high rates of relapse. We evaluated the safety and efficacy of the combination of daunorubicin, cytarabine (DA), gemtuzumab ozogamicin (GO) and midostaurin (DAGO+m) for younger patients with newly diagnosed FLT3mut AML in the UK NCRI AML19 trial. 195 patients were randomised to receive DA with either one or two doses of GO (DAGO1 and DAGO2). 77 had a FLT3 mutation (60 had FLT3-ITD) and received midostaurin for two weeks after each chemotherapy course and then as maintainance for one year unless transplanted. 39 patients received midostaurin with DAGO1 (DAGO1+m) and 38 with DAGO2 (DAGO2+m). Their median age was 51y (range 20-74) and 16 (20%) were aged >60y. The overall response rate (CR + CRi) was 91%. Day 30 and day 60 mortality was 0% with no increase in toxicity compared to patients treated contemporaneously with DAGO1 and DAGO2 without midostaurin. 2y overall survival was 77%. 2y event-free survival and cumulative incidence of relapse were 62% and 31% respectively. MRD clearance was enhanced compared to patients with FLT3-mutated AML treated with DAGO1 and DAGO2 without midostaurin. 81% of evaluable patients were NPM1 MRD negative by RT-qPCR in the peripheral blood after course 2 (76% with DAGO1+m and 86% with DAGO2+m), 79% were MRD negative in the bone marrow by FLT3-ITD NGS, and all patients had FLT3-MRD levels below 0.01%. DAGO+m appears safe and effective . DAGO2+m will now be evaluated in a randomised study (OPTIMISE-FLT3, ISRCTN 34016918). Trial: ISRCTN78449203

Item Type:	Article
Date Type:	Published Online
Status:	In Press
Schools:	Schools > Medicine Research Institutes & Centres > Centre for Trials Research (CNTRR)
Publisher:	American Society of Hematology (ASH Publications)
ISSN:	2473-9529
Date of First Compliant Deposit:	7 October 2025
Date of Acceptance:	3 September 2025
Last Modified:	07 Oct 2025 10:15
URI:	https://orca.cardiff.ac.uk/id/eprint/181514

Actions (repository staff only)

Edit Item